Title
Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries
Date Issued
01 March 2018
Access level
open access
Resource Type
journal article
Author(s)
Alonso J.
Liu Z.
Evans-Lacko S.
Sadikova E.
Sampson N.
Chatterji S.
Abdulmalik J.
Aguilar-Gaxiola S.
Al-Hamzawi A.
Andrade L.H.
Bruffaerts R.
Cardoso G.
Cia A.
Florescu S.
de Girolamo G.
Gureje O.
Haro J.M.
He Y.
de Jonge P.
Karam E.G.
Kawakami N.
Kovess-Masfety V.
Lee S.
Levinson D.
Medina-Mora M.E.
Navarro-Mateu F.
Pennell B.E.
Piazza M.
Posada-Villa J.
ten Have M.
Zarkov Z.
Kessler R.C.
Thornicroft G.
Publisher(s)
Blackwell Publishing Inc.
Abstract
Background: Anxiety disorders are a major cause of burden of disease. Treatment gaps have been described, but a worldwide evaluation is lacking. We estimated, among individuals with a 12-month DSM-IV (where DSM is Diagnostic Statistical Manual) anxiety disorder in 21 countries, the proportion who (i) perceived a need for treatment; (ii) received any treatment; and (iii) received possibly adequate treatment. Methods: Data from 23 community surveys in 21 countries of the World Mental Health (WMH) surveys. DSM-IV mental disorders were assessed (WHO Composite International Diagnostic Interview, CIDI 3.0). DSM-IV included posttraumatic stress disorder among anxiety disorders, while it is not considered so in the DSM-5. We asked if, in the previous 12 months, respondents felt they needed professional treatment and if they obtained professional treatment (specialized/general medical, complementary alternative medical, or nonmedical professional) for “problems with emotions, nerves, mental health, or use of alcohol or drugs.” Possibly adequate treatment was defined as receiving pharmacotherapy (1+ months of medication and 4+ visits to a medical doctor) or psychotherapy, complementary alternative medicine or nonmedical care (8+ visits). Results: Of 51,547 respondents (response = 71.3%), 9.8% had a 12-month DSM-IV anxiety disorder, 27.6% of whom received any treatment, and only 9.8% received possibly adequate treatment. Of those with 12-month anxiety only 41.3% perceived a need for care. Lower treatment levels were found for lower income countries. Conclusions: Low levels of service use and a high proportion of those receiving services not meeting adequacy standards for anxiety disorders exist worldwide. Results suggest the need for improving recognition of anxiety disorders and the quality of treatment.
Start page
195
End page
208
Volume
35
Issue
3
Language
English
OCDE Knowledge area
Salud pública, Salud ambiental Psiquiatría
Scopus EID
2-s2.0-85042905430
PubMed ID
Source
Depression and Anxiety
ISSN of the container
10914269
Sponsor(s)
The World Health Organization World Mental Health (WMH) Survey Initiative is supported by the U.S. National Institute of Mental Health (NIMH; R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the U.S. Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc., GlaxoSmithKline, and Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis Coordination Centers for assistance with instrumentation, fieldwork, and consultation on data analysis. None of the funders had any role in the design, analysis, interpretation of results, or preparation of this paper. The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of the World Health Organization, other sponsoring organizations, agencies, or governments. The Argentina survey—Estudio Argentino de Epidemiología en Salud Mental (EASM)—was supported by a grant from the Argentinian Ministry of Health (Ministerio de Salud de la Nación). The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research Foundation (FAPESP) Thematic Project Grant 03/00204-3. The Brazilian National Council for Scientific and Technological Development supports Dr. Laura Andrade—(CNPq Grant #307623/2013-0). The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. The Chinese World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Colombian National Study of Mental Health (NSMH) is supported by the Ministry of Social Protection. The Mental Health Study Medellín—Colombia was carried out and supported jointly by the Center for Excellence on Research in Mental Health (CES University) and the Secretary of Health of Medellín. The ESEMeD project is funded by the European Commission (Contracts QLG5-1999-01042, SANCO 2004123, and EAHC 20081308) (the Piedmont Region, Italy), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. Implementation of the Iraq Mental Health Survey (IMHS) and data entry were carried out by the staff of the Iraqi MOH and MOP with direct support from the Iraqi IMHS team with funding from both the Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006) from the Japan Ministry of Health, Labour and Welfare. The Lebanese Evaluation of the Burden of Ailments and Needs Of the Nation (L.E.B.A.N.O.N.) is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health/ Fogarty International Center (R03 TW006481-01), anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from, Algorithm, AstraZeneca, Benta, Bella Pharma, Eli Lilly, Glaxo Smith Kline, Lundbeck, Novartis, Servier, OmniPharma, Phenicia, Pfizer, UPO. The Mexican National Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544- H), with supplemental support from the PanAmerican Health Organization (PAHO). The Nigerian Survey of Mental Health and Wellbeing (NSMHW) is supported by the WHO (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria. The Peruvian World Mental Health Study was funded by the National Institute of Health of the Ministry of Health of Peru. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology (FCT), and Ministry of Health. The Romania WMH study projects “Policies in Mental Health Area” and “National Study regarding Mental Health and Services Use” were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, SC, Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania SRL. The Psychiatric Enquiry to General Population in Southeast Spain—Murcia (PEGASUS-Murcia) Project has been financed by the Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejería de Sanidad y Política Social) and Fundación para la Formación e Investigación Sanitarias (FFIS) of Murcia. The U.S. National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA). SEL (Sara Evans-Lacko) currently holds a Starting Grant from the European Research Council (337673). The Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. Dr. Thornicroft is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust. Dr. Thornicroft acknowledges support from the following: the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust; the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Unit awarded to South London and Maudsley NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust; the European Union Seventh Framework Programme (FP7/2007-2013) Emerald project. Grant sponsor: U.S. National Institute of Mental Health (NIMH); Grant number: R01 MH070884; Grant sponsors: John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the U.S. Public Health Service; Grant numbers: R13-MH066849, R01-MH069864, and R01DA016558; Grant sponsor: Fogarty International Center (FIRCA); Grant number: R03-TW006481; Grant sponsor: Pan American Health Organization; Grant sponsor: Eli Lilly and Company; Grant sponsor: Ortho-McNeil Pharmaceutical Inc.; Grant sponsor: GlaxoSmithKline; Grant sponsor: Bristol-Myers Squibb; Grant sponsor: Argentinian Ministry of Health (Ministerio de Salud de la Nación); Grant sponsor: State of São Paulo Research Foundation (FAPESP) Thematic Project; Grant number: 03/00204-3; Grant sponsor: The Brazilian National Council for Scientific and Technological Development; Grant number: 307623/2013-0; Grant sponsor: Ministry of Health and the National Center for Public Health Protection; Grant sponsor: Ministry of Social Protection; Grant sponsors: Center for Excellence on Research in Mental Health (CES University) and the Secretary of Health of Medellín; Grant sponsor: European Commission; Grant numbers: QLG5-1999-01042, SANCO 2004123, and EAHC 20081308; Grant sponsor: Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain; Grant number: FIS 00/0028; Grant sponsor: Ministerio de Ciencia y Tecnología, Spain; Grant number: SAF 2000-158-CE; Grant sponsor: Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III; Grant numbers: CIBER CB06/02/0046 and RETICS RD06/0011 REM-TAP; Grant sponsor: United Nations Development Group Iraq Trust Fund (UNDG ITF); Grant sponsor: Ministry of Health; Grant sponsor: Israel National Institute for Health Policy and Health Services Research; Grant sponsor: National Insurance Institute of Israel; Grant sponsor: Japan Ministry of Health, Labour and Welfare; Grant numbers: H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, and H25-SEISHIN-IPPAN-006; Grant sponsor: Lebanese Ministry of Public Health; Grant sponsor: the WHO (Lebanon); Grant sponsor: National Institute of Health/ Fogarty International Center; Grant number: R03 TW006481-01; Grant sponsor: Algorithm; Grant sponsor: AstraZeneca; Grant sponsor: Benta; Grant sponsor: Bella Pharma; Grant sponsor: Eli Lilly; Grant sponsor: Glaxo Smith Kline; Grant sponsor: Lundbeck; Grant sponsor: Novartis; Grant sponsor: OmniPharma; Grant sponsor: Pfizer; Grant sponsor: Phenicia; Grant sponsor: Servier; Grant sponsor: UPO; Grant sponsor: the National Institute of Psychiatry Ramon de la Fuente; Grant number: INPRFMDIES 4280; Grant sponsor: National Council on Science and Technology; Grant number: CONACyT-G30544-H; Grant sponsor: WHO (Geneva); Grant sponsor: the WHO (Nigeria); Grant sponsor: the Federal Ministry of Health, Abuja, Nigeria; Grant sponsor: National Institute of Health of the Ministry of Health of Peru; Grant sponsor: Champalimaud Foundation; Grant sponsor: Gulbenkian Foundation; Grant sponsor: Foundation for Science and Technology (FCT); Grant sponsor: Ministry of Health (Portugal); Grant sponsor: Metro Media Transilvania; Grant sponsor: the National Institute of Statistics-National Centre for Training in Statistics, SC; Grant sponsor: Cheyenne Services SRL, Statistics Netherlands; Grant sponsor: Ministry of Public Health (Romania); Grant Sponsor: Eli Lilly Romania SRL; Regional Health Authorities of Murcia; Grant sponsor: National Institute of Mental Health (NIMH); Grant number: U01-MH60220; Grant sponsor: National Institute of Drug Abuse (NIDA); Grant sponsor: the Substance Abuse and Mental Health Services Administration (SAMHSA); Grant sponsor: the Robert Wood Johnson Foundation (RWJF); Grant number: 044708; Grant sponsor: the John W. Alden Trust; Grant sponsor: National Institute for Health Research (NIHR); Grant sponsor: Department of Health via the National Institute for Health Research (NIHR); Grant sponsor: European Union Seventh Framework Programme; Grant number: FP7/2007-2013; Grant sponsor: European Research Council; Grant number: 337673. None of the funders had any role in the design, analysis, interpretation of results, or preparation of this paper. The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of the World Health Organization, other sponsoring organizations, agencies, or governments. In the past 3 years, Dr. Kessler received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. Kessler is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research. Dr. Evans-Lacko received consulting fees from Lundbeck not connected to this research. Dr. Haro received personal fees from Lundbeck. Dr. Kawakami served as a consultant for Junpukai Foundation, SB At Work, Sekisui Co., Ltd., and received grant funding from Infosoft Technologies, Ministry of Health, Labour, and Welfare, and Japan Society for Promotion of Science. The other authors report no biomedical financial interests or potential conflicts of interest.
Sources of information: Directorio de Producción Científica Scopus